Loading stock data…
Tandem Diabetes Care, Inc. (TNDM)
$19.88-0.02 (-0.10%)
Market ClosedLast close Sep 8
Tandem Diabetes Care, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tandem Diabetes Care, Inc. in the Healthcare sector is trading at $19.88 with a market capitalization of $1.6B. Wall Street consensus targets $28.70 (20 analysts), implying a +44.4% move over the next 12 months. The stock is currently 33% below its 52-week high of $29.65, remaining 0.5% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +44.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 32) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $254.56M↑ | $247.22M↓ | $290.38M↑ | $249.25M↑ | $240.68M |
| Gross Profit | $144.78M↑ | $136.79M↓ | $167.46M↑ | $134.29M↑ | $125.86M |
| Operating Income | -$13.79M↑ | -$17.43M↓ | $8.29M↑ | -$22.86M↑ | -$31.86M |
| Net Income | -$21.17M↓ | -$20.39M↓ | -$589,000↑ | -$21.16M↑ | -$52.40M |
Peer Comparison
JNJUNHPFE
Fundamentals
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.58B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.54
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-48.56%
Volume
Today's trading volume
1.64M
Recent News
MiniMed submits new patch pump for FDA clearance
The diabetes tech firm is preparing for the launch of new devices, including a tubeless insulin pump and a fully closed loop automated insulin delivery system.
3 Reasons TNDM is Risky and 1 Stock to Buy Instead
Over the last six months, Tandem Diabetes’s shares have sunk to $22.45, producing a disappointing 13.7% loss - a stark contrast to the S&P 500’s 10.5% gain. This might have investors contemplating their next move.
Can PODD Sustain Growth After Its 2026 Guidance Reset and Q2 Beat?
Insulet's Q2 beat and stronger margins contrast with a 2026 growth reset, putting U.S. Type 2 retention at the center of its outlook.
Nvidia initiated, Teradyne downgraded: Wall Street's top analyst calls
Nvidia initiated, Teradyne downgraded: Wall Street's top analyst calls
Tandem Diabetes Care Maps Growth Plan With Pharmacy Shift and Tubeless Mobi
Tandem Diabetes Care (NASDAQ:TNDM) highlighted its plans to expand insulin pump adoption through a shift to pharmacy distribution in the U.S., direct sales in additional international markets and upcoming product launches, including a tubeless version of its Tandem Mobi pump. Speaking at Canaccord’